Detalhe da pesquisa
1.
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 25(5): 572-587, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38561010
2.
Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go?
Oncologist
; 29(5): e699-e707, 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38127280
3.
Oligometastatic disease from differentiated thyroid cancer: best treatment schemes.
Curr Opin Oncol
; 35(1): 15-21, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36475458
4.
Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC).
Future Oncol
; 19(3): 193-203, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36974574
5.
International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic.
Lancet Oncol
; 23(12): e544-e551, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36455583
6.
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Oncologist
; 27(2): e194-e198, 2022 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35641218
7.
Relevance of apparent diffusion coefficient features for a radiomics-based prediction of response to induction chemotherapy in sinonasal cancer.
NMR Biomed
; 35(4): e4265, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32009265
8.
Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design.
Future Oncol
; 18(14): 1669-1678, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35172587
9.
Methodological approach for determining the Minimal Important Difference and Minimal Important Change scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module (EORTC QLQ-HN43) exemplified by the Swallowing scale.
Qual Life Res
; 31(3): 841-853, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34272632
10.
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Lancet Oncol
; 22(6): 848-857, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34000246
11.
Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis.
Int J Cancer
; 149(3): 675-683, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33844854
12.
Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer.
Mod Pathol
; 34(3): 532-541, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33239737
13.
The hidden curve behind COVID-19 outbreak: the impact of delay in treatment initiation in cancer patients and how to mitigate the additional risk of dying-the head and neck cancer model.
Cancer Causes Control
; 32(5): 459-471, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33704627
14.
Prognostic role of pre-treatment magnetic resonance imaging (MRI)-based radiomic analysis in effectively cured head and neck squamous cell carcinoma (HNSCC) patients.
Acta Oncol
; 60(9): 1192-1200, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34038324
15.
Management of loco-regionally advanced squamous laryngeal cancer in elderly patients.
Eur Arch Otorhinolaryngol
; 278(3): 771-779, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32656672
16.
Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus.
Lancet Oncol
; 21(7): e350-e359, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32534633
17.
Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life.
Cancer
; 126(9): 1888-1894, 2020 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32031693
18.
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Lancet
; 393(10167): 156-167, 2019 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30509740
19.
Phase III Randomized Study of Induction Chemotherapy Followed by Definitive Radiotherapy + Cetuximab Versus Chemoradiotherapy in Squamous Cell Carcinoma of Head and Neck: The INTERCEPTOR-GONO Study (NCT00999700).
Oncology
; 98(11): 763-770, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32629446
20.
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412.
Future Oncol
; 16(18): 1235-1243, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32490686